SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-024223
Filing Date
2022-11-10
Accepted
2022-11-10 09:20:51
Documents
54
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q lrmr-20220930.htm   iXBRL 10-Q 2026904
2 EX-31.1 lrmr-ex31_1.htm EX-31.1 13670
3 EX-31.2 lrmr-ex31_2.htm EX-31.2 13810
4 EX-32.1 lrmr-ex32_1.htm EX-32.1 25378
  Complete submission text file 0000950170-22-024223.txt   7098544

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT lrmr-20220930_cal.xml EX-101.CAL 39992
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lrmr-20220930_lab.xml EX-101.LAB 372139
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lrmr-20220930.xsd EX-101.SCH 41853
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lrmr-20220930_pre.xml EX-101.PRE 259777
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT lrmr-20220930_def.xml EX-101.DEF 140152
48 EXTRACTED XBRL INSTANCE DOCUMENT lrmr-20220930_htm.xml XML 1333941
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

IRS No.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36510 | Film No.: 221375297
SIC: 2834 Pharmaceutical Preparations